{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:21:59Z","timestamp":1783563719850,"version":"3.55.0"},"reference-count":181,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"India Ministry of Science & Technology Department of Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.drudis.2025.104339","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T18:36:19Z","timestamp":1742409379000},"page":"104339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Emerging role of deubiquitinases in modulating cancer chemoresistance"],"prefix":"10.1016","volume":"30","author":[{"given":"Sukeerthi","family":"Dasharathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pranay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh K.","family":"Devadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthi","family":"Karyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104339_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2025.104339_b0010","series-title":"Therapeutic Approaches in Cancer Treatment","first-page":"1","article-title":"Introduction and overview of cancer therapeutics","author":"Qazi","year":"2023"},{"key":"10.1016\/j.drudis.2025.104339_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110009","article-title":"Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine","volume":"125","author":"Bashraheel","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2025.104339_b0020","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.1974.03240070065040","article-title":"Thoughts on cancer chemotherapy and combination modality therapy (1974)","volume":"230","author":"Skipper","year":"1974","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2025.104339_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0030","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104339_b0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pharmthera.2016.02.008","article-title":"Cancer stem cells and chemoresistance: the smartest survives the raid","volume":"160","author":"Zhao","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104339_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024665","article-title":"Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production","volume":"6","author":"Oliva","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104339_b0045","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.3390\/cancers14194562","article-title":"Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance","volume":"14","author":"Ashrafi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104339_b0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","article-title":"The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities","volume":"28","author":"Damgaard","year":"2021","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2025.104339_b0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1042\/BST0370937","article-title":"The emerging complexity of protein ubiquitination","volume":"37","author":"Komander","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.drudis.2025.104339_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303807","article-title":"Deubiquitylating enzymes in cancer and immunity","volume":"10","author":"Ren","year":"2023","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0065","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/cr.2016.38","article-title":"Substrate specificity of the ubiquitin and Ubl proteases","volume":"26","author":"Ronau","year":"2016","journal-title":"Cell Res"},{"key":"10.1016\/j.drudis.2025.104339_b0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-4419-6676-6_6","article-title":"Mechanism, specificity and structure of the deubiquitinases","volume":"54","author":"Komander","year":"2010","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.drudis.2025.104339_b0075","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/ncb2346","article-title":"USP15 is a deubiquitylating enzyme for receptor-activated SMADs","volume":"13","author":"Inui","year":"2011","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.drudis.2025.104339_b0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/cmi.2011.59","article-title":"Regulation of NF-\u03baB signaling by the A20 deubiquitinase","volume":"9","author":"Shembade","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2025.104339_b0085","article-title":"Post-translational modifications of deubiquitinating enzymes: expanding the ubiquitin code","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104339_b0090","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.R110.003871","article-title":"Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes","volume":"10","author":"Lee","year":"2011","journal-title":"Mol Cell Proteom"},{"key":"10.1016\/j.drudis.2025.104339_b0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12265-019-09909-x","article-title":"The role of deubiquitinases in vascular diseases","volume":"13","author":"Wang","year":"2019","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.drudis.2025.104339_b0100","doi-asserted-by":"crossref","first-page":"T35","DOI":"10.1530\/ERC-14-0516","article-title":"Deubiquitinases and the new therapeutic opportunities offered to cancer","volume":"2015","author":"Pfoh","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.drudis.2025.104339_b0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2021.10.027","article-title":"Deubiquitinases: from mechanisms to their inhibition by small molecules","volume":"82","author":"Lange","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2025.104339_b0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41419-019-1512-6","article-title":"Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy","volume":"10","author":"He","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104339_b0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clbc.2022.11.006","article-title":"USP22 Contributes to chemoresistance, stemness, and EMT phenotype of triple-negative breast cancer cells by regulating the Warburg effect via c-Myc deubiquitination","volume":"23","author":"Li","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.drudis.2025.104339_b0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2174\/1568009620666200503045400","article-title":"USP48 sustains chemoresistance and metastasis in ovarian cancer","volume":"20","author":"Lei","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.drudis.2025.104339_b0125","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.7150\/jca.52158","article-title":"USP11 induce resistance to 5-Fluorouracil in colorectal cancer through activating autophagy by stabilizing VCP","volume":"12","author":"Sun","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.drudis.2025.104339_b0130","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.7150\/ijbs.61128","article-title":"Deubiquitinase PSMD7 promotes the proliferation, invasion, and cisplatin resistance of gastric cancer cells by stabilizing RAD23B","volume":"17","author":"Wang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0135","doi-asserted-by":"crossref","first-page":"30962","DOI":"10.18632\/oncotarget.8821","article-title":"USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment","volume":"7","author":"Vogel","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104339_b0140","doi-asserted-by":"crossref","first-page":"49033","DOI":"10.18632\/oncotarget.16931","article-title":"WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104339_b0145","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1074\/jbc.RA118.006057","article-title":"Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis","volume":"294","author":"Liu","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104339_b0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12032-022-01749-1","article-title":"Molecular perspective on targeted therapy in breast cancer: a review of current status","volume":"39","author":"Demir Cetinkaya","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0155","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge","volume":"22","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104339_b0160","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13046-018-0934-9","article-title":"Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity","volume":"37","author":"Qin","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202205873","article-title":"Phosphorylation of USP29 by CDK1 governs TWIST1 stability and oncogenic functions","volume":"10","author":"Guan","year":"2023","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/0008-5472.CAN-18-0753","article-title":"TGF\u03b2-activated USP27X deubiquitinase regulates cell migration and chemoresistance via stabilization of Snail1","volume":"79","author":"Lambies","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0175","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1002\/jcp.30763","article-title":"Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple-negative breast cancer by stabilizing Snail1","volume":"237","author":"Guan","year":"2022","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2025.104339_b0180","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/s41388-018-0134-2","article-title":"The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104339_b0185","doi-asserted-by":"crossref","first-page":"553","DOI":"10.18632\/oncotarget.23074","article-title":"OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer","volume":"9","author":"Chiu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104339_b0190","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.3390\/cells11203294","article-title":"USP7 Induces chemoresistance in triple-negative breast cancer via deubiquitination and stabilization of ABCB1","volume":"11","author":"Lin","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104339_b0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cellsig.2018.09.010","article-title":"Jab1\/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51","volume":"53","author":"Liu","year":"2019","journal-title":"Cell Signal"},{"key":"10.1016\/j.drudis.2025.104339_b0200","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1101\/gad.289439.116","article-title":"A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination","volume":"30","author":"Luo","year":"2016","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2025.104339_b0205","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/onc.2015.208","article-title":"OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance","volume":"35","author":"Karunarathna","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104339_b0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10549-022-06711-3","article-title":"USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells","volume":"196","author":"Su","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.drudis.2025.104339_b0215","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/gyno.1998.5304","article-title":"Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study","volume":"72","author":"Homesley","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0220","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2025.104339_b0225","first-page":"277","article-title":"USP39 promotes ovarian cancer malignant phenotypes and carboplatin chemoresistance","volume":"55","author":"Wang","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0230","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41392-021-00580-w","article-title":"The deubiquitinase USP11 promotes ovarian cancer chemoresistance by stabilizing BIP","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104339_b0235","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41418-019-0339-0","article-title":"JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2025.104339_b0240","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3892\/ijo.2016.3494","article-title":"BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer","volume":"49","author":"Habata","year":"2016","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0245","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ygyno.2023.12.031","article-title":"UCHL-3 as a potential biomarker of ovarian cancer","volume":"182","author":"Yang","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0250","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1073\/pnas.1814742116","article-title":"MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer","volume":"116","author":"Wu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104339_b0255","doi-asserted-by":"crossref","first-page":"15752","DOI":"10.1038\/ncomms15752","article-title":"USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104339_b0260","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav3235","article-title":"USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability","volume":"5","author":"Sonego","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2025.104339_b0265","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104339_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1060909","article-title":"The role of long noncoding RNAs in therapeutic resistance in cervical cancer","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2025.104339_b0275","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.omto.2020.05.008","article-title":"miR-16-5p\/PDK4-mediated metabolic reprogramming is involved in chemoresistance of cervical cancer","volume":"17","author":"Zhao","year":"2020","journal-title":"Molecular Therapy-Oncolytics"},{"key":"10.1016\/j.drudis.2025.104339_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118835","article-title":"HAUSP stabilizes Cdc25A and protects cervical cancer cells from DNA damage response","volume":"1867","author":"Das","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.drudis.2025.104339_b0285","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1634\/theoncologist.2016-0062","article-title":"Chemotherapy for endometrial cancer in adjuvant and advanced disease settings","volume":"21","author":"Bestvina","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2025.104339_b0290","first-page":"1317","article-title":"Chemoresistance and targeting of growth factors\/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer","volume":"8","author":"Guo","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0295","first-page":"204","article-title":"Second and third line treatment in advanced non-small cell lung cancer","volume":"8","author":"Favaretto","year":"2009","journal-title":"Discov Med"},{"key":"10.1016\/j.drudis.2025.104339_b0300","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","article-title":"Overcoming chemotherapy resistance in SCLC","volume":"16","author":"Herzog","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0305","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1101\/gad.340133.120","article-title":"MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity","volume":"34","author":"Grunblatt","year":"2020","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2025.104339_b0310","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/cbdd.13688","article-title":"OTU deubiquitinase 5 inhibits the progression of non-small cell lung cancer via regulating p53 and PDCD5","volume":"96","author":"Kang","year":"2020","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2025.104339_b0315","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41374-021-00725-z","article-title":"Ubiquitin-specific protease 35 (USP35) mediates cisplatin-induced apoptosis by stabilizing BIRC3 in non-small cell lung cancer","volume":"102","author":"Liu","year":"2022","journal-title":"Lab Invest"},{"key":"10.1016\/j.drudis.2025.104339_b0320","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41419-020-03008-5","article-title":"USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stress","volume":"11","author":"Wu","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104339_b0325","doi-asserted-by":"crossref","first-page":"10783","DOI":"10.1074\/jbc.M115.700047","article-title":"Ubiquitin-specific peptidase 10 (USP10) deubiquitinates and stabilizes MutS homolog 2 (MSH2) to regulate cellular sensitivity to DNA damage","volume":"291","author":"Zhang","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104339_b0330","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/1541-7786.MCR-19-0053","article-title":"USP22 interacts with PALB2 and promotes chemotherapy resistance via homologous recombination of DNA double-strand breaks","volume":"18","author":"Nardi","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0335","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/bab.2386","article-title":"The role of USP51 in attenuating chemosensitivity of lung cancer cells to cisplatin by regulating DNA damage response","volume":"70","author":"Zhou","year":"2023","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.drudis.2025.104339_b0340","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cac2.12460","article-title":"USP51\/PD-L1\/ITGB1-deployed juxtacrine interaction plays a cell-intrinsic role in promoting chemoresistant phenotypes in non-small cell lung cancer","volume":"43","author":"Li","year":"2023","journal-title":"Cancer Commun"},{"key":"10.1016\/j.drudis.2025.104339_b0345","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.7150\/thno.42096","article-title":"The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase","volume":"10","author":"Ding","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2025.104339_b0350","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.3390\/curroncol30110694","article-title":"A simple overview of pancreatic cancer treatment for clinical oncologists","volume":"30","author":"Garajov\u00e1","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0355","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.3390\/ijms20184504","article-title":"Chemoresistance in pancreatic cancer","volume":"20","author":"Zeng","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2022.101787","article-title":"Down-regulation of USP22 reduces cell stemness and enhances the sensitivity of pancreatic cancer cells to cisplatin by inactivating the Wnt\/\u03b2-catenin pathway","volume":"77","author":"Li","year":"2022","journal-title":"Tissue Cell"},{"key":"10.1016\/j.drudis.2025.104339_b0365","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.freeradbiomed.2021.08.006","article-title":"Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells","volume":"174","author":"Grattarola","year":"2021","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.drudis.2025.104339_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115359","article-title":"USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2","volume":"166","author":"Cui","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2025.104339_b0375","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/embj.201695669","article-title":"USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling","volume":"36","author":"Luo","year":"2017","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2025.104339_b0380","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s10637-020-00951-0","article-title":"Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance","volume":"38","author":"Chen","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drudis.2025.104339_b0385","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2018.08.010","article-title":"USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy","volume":"436","author":"Ma","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2025.104339_b0390","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3390\/cancers12082116","article-title":"Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma","volume":"12","author":"Marin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104339_b0395","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0330","article-title":"Docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in metastatic and unresectable gastric\/gastroesophageal junction adenocarcinoma: a Phase II study with long-term follow-up","volume":"24","author":"Rosenberg","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2025.104339_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216712","article-title":"Modulation of YBX1-mediated PANoptosis inhibition by PPM1B and USP10 confers chemoresistance to oxaliplatin in gastric cancer","volume":"587","author":"Lin","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2025.104339_b0405","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3892\/mmr.2016.5413","article-title":"miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD","volume":"14","author":"Zhu","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.drudis.2025.104339_b0410","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1002\/cam4.1770","article-title":"USP14 as a novel prognostic marker promotes cisplatin resistance via Akt\/ERK signaling pathways in gastric cancer","volume":"7","author":"Fu","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.drudis.2025.104339_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101779","article-title":"Inhibition of USP11 sensitizes gastric cancer to chemotherapy via suppressing RhoA and Ras-mediated signaling pathways","volume":"46","author":"Liu","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.drudis.2025.104339_b0420","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.7150\/ijbs.43117","article-title":"USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2","volume":"16","author":"Dou","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0425","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00018-022-04131-6","article-title":"Molecular mechanisms associated with chemoresistance in esophageal cancer","volume":"79","author":"Lohan-Code\u00e7o","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0430","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.05.020","article-title":"Oxaliplatin\/capecitabine or carboplatin\/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): long-term results of a randomised controlled trial","volume":"153","author":"Mukherjee","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2025.104339_b0435","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12032-023-02272-7","article-title":"USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells","volume":"41","author":"Hou","year":"2023","journal-title":"Med Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0440","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/genes13050819","article-title":"The deubiquitinase USP39 promotes esophageal squamous cell carcinoma malignancy as a splicing factor","volume":"13","author":"Zhu","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.drudis.2025.104339_b0445","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbrc.2022.01.019","article-title":"The deubiquitinating enzyme USP20 regulates the stability of the MCL1 protein","volume":"593","author":"Feng","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104339_b0450","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002874","article-title":"OTUD1 Activates caspase-independent and caspase-dependent apoptosis by promoting AIF nuclear translocation and MCL1 degradation","volume":"8","author":"Luo","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0455","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.celrep.2019.12.017","article-title":"TRIM32\/USP11 balances ARID1A stability and the oncogenic\/tumor-suppressive status of squamous cell carCinoma","volume":"30","author":"Luo","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104339_b0460","article-title":"Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: a mini-review","volume":"9","author":"Chen","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2025.104339_b0465","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/annonc\/mdi193","article-title":"Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study","volume":"16","author":"Kalofonos","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0470","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ebiom.2019.10.039","article-title":"The deubiquitinating enzyme PSMD14 facilitates tumor growth and chemoresistance through stabilizing the ALK2 receptor in the initiation of BMP6 signaling pathway","volume":"49","author":"Seo","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2025.104339_b0475","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbrc.2022.03.138","article-title":"c-MYC-USP49-BAG2 axis promotes proliferation and chemoresistance of colorectal cancer cells in vitro","volume":"607","author":"Tu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104339_b0480","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1128\/MCB.00695-13","article-title":"Downregulation of PHLPP expression contributes to hypoxia-induced resistance to chemotherapy in colon cancer cells","volume":"33","author":"Wen","year":"2013","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2025.104339_b0485","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41418-023-01228-8","article-title":"USP51 facilitates colorectal cancer stemness and chemoresistance by forming a positive feed-forward loop with HIF1A","volume":"30","author":"Mu","year":"2023","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2025.104339_b0490","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12916-023-02826-6","article-title":"Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3\/AR\/RASGRP3 axis","volume":"21","author":"Zheng","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.drudis.2025.104339_b0495","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41389-023-00458-2","article-title":"USP35 promotes cell proliferation and chemotherapeutic resistance through stabilizing FUCA1 in colorectal cancer","volume":"12","author":"Xiao","year":"2023","journal-title":"Oncogenesis"},{"key":"10.1016\/j.drudis.2025.104339_b0500","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/0008-5472.CAN-22-2145","article-title":"CSN6 mediates nucleotide metabolism to promote tumor development and chemoresistance in colorectal cancer","volume":"83","author":"Zou","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0505","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41389-020-0234-z","article-title":"USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3","volume":"9","author":"Zhan","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.drudis.2025.104339_b0510","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1159\/000489156","article-title":"Ubiquitin-specific peptidase 22 contributes to colorectal cancer stemness and chemoresistance via Wnt\/\u03b2-catenin pathway","volume":"46","author":"Jiang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.drudis.2025.104339_b0515","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.celrep.2013.02.014","article-title":"Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA","volume":"3","author":"Brinkmann","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104339_b0520","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/s41418-019-0303-z","article-title":"DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2025.104339_b0525","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5306\/wjco.v8.i3.203","article-title":"Evolving role of sorafenib in the management of hepatocellular carcinoma","volume":"8","author":"Ziogas","year":"2017","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0530","first-page":"22","article-title":"Further understanding of mechanisms involved in liver cancer chemoresistance","volume":"3","author":"Oscar","year":"2017","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.drudis.2025.104339_b0535","doi-asserted-by":"crossref","first-page":"14999","DOI":"10.18632\/aging.203061","article-title":"Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases","volume":"13","author":"Zhu","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.drudis.2025.104339_b0540","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.12659\/MSM.908925","article-title":"Upregulation of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) mediates the reversal effect of verapamil on chemo-resistance to adriamycin of hepatocellular carcinoma","volume":"24","author":"Yang","year":"2018","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.drudis.2025.104339_b0545","first-page":"2206","article-title":"Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress-related autophagy in hepatocellular carcinoma","volume":"40","author":"Liu","year":"2018","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2025.104339_b0550","first-page":"121","article-title":"Down-regulation of CYLD as a trigger for NF-\u03baB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells","volume":"38","author":"Urbanik","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0555","doi-asserted-by":"crossref","first-page":"24728","DOI":"10.18632\/oncotarget.15798","article-title":"USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104339_b0560","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/1878-0261.12067","article-title":"USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1\/AKT\/MRP1 signaling pathway","volume":"11","author":"Ling","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0565","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1111\/jcmm.16709","article-title":"USP11 degrades KLF4 via its deubiquitinase activity in liver diseases","volume":"25","author":"Yang","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2025.104339_b0570","first-page":"34","article-title":"Lymphoma: diagnosis and treatment","volume":"101","author":"Lewis","year":"2020","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.drudis.2025.104339_b0575","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2001-1326-2-3","article-title":"Mechanisms of chemoresistance in cancer stem cells","volume":"2","author":"Abdullah","year":"2013","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.drudis.2025.104339_b0580","doi-asserted-by":"crossref","first-page":"851","DOI":"10.15252\/emmm.201506047","article-title":"USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma","volume":"8","author":"Engel","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2025.104339_b0585","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2003.06.128","article-title":"Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951","volume":"21","author":"Wells","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0590","first-page":"233","article-title":"Lysosome-mediated chemoresistance in acute myeloid leukemia","volume":"5","author":"Cuesta-Casanovas","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.drudis.2025.104339_b0595","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/mc.23330","article-title":"ALKBH5-mediated m6A-demethylation of USP1 regulated T-cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B","volume":"60","author":"Gong","year":"2021","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.drudis.2025.104339_b0600","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41419-022-04531-3","article-title":"HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p\/USP6\/GLS1 axis","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104339_b0605","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41375-020-0878-x","article-title":"Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy","volume":"35","author":"Cartel","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2025.104339_b0610","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13046-019-1502-7","article-title":"De-regulated STAT5A\/miR-202-5p\/USP15\/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance","volume":"39","author":"Nie","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0615","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/nchembio.2486","article-title":"Inhibition of USP10 induces degradation of oncogenic FLT3","volume":"13","author":"Weisberg","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2025.104339_b0620","first-page":"64","article-title":"Chemoresistance and multiple myeloma: from biological to clinical aspects","volume":"13","author":"Rossi","year":"1995","journal-title":"Stem Cells"},{"key":"10.1016\/j.drudis.2025.104339_b0625","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/164_2017_10","article-title":"Mechanisms of resistance in multiple myeloma","volume":"249","author":"Papadas","year":"2018","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.drudis.2025.104339_b0630","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41388-021-02167-9","article-title":"Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104339_b0635","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1038\/onc.2017.172","article-title":"Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"36","author":"Song","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104339_b0640","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.7150\/ijbs.11439","article-title":"Insights into chemoresistance of prostate cancer","volume":"11","author":"Zhang","year":"2015","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0645","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2025.104339_b0650","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s13046-019-1457-8","article-title":"USP7 is a novel deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis","volume":"38","author":"Peng","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0655","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/2159-8290.CD-11-0219","article-title":"MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer","volume":"2","author":"Benassi","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2025.104339_b0660","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.molcel.2018.06.036","article-title":"DUB3 Promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4","volume":"71","author":"Jin","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2025.104339_b0665","unstructured":"National Cancer Institute. Drugs Approved for Head and Neck Cancer. www.cancer.gov\/about-cancer\/treatment\/drugs\/head-neck [Accessed March 13, 2025]."},{"key":"10.1016\/j.drudis.2025.104339_b0670","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.640392","article-title":"Molecular mechanisms of chemotherapy resistance in head and neck cancers","volume":"11","author":"Kanno","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0675","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.7150\/thno.48375","article-title":"Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1\/Akt\/SOX2-mediated stemness","volume":"11","author":"Jing","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2025.104339_b0680","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12935-021-02060-1","article-title":"JOSD1 promotes proliferation and chemoresistance of head and neck squamous cell carcinoma under the epigenetic regulation of BRD4","volume":"21","author":"Jing","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.drudis.2025.104339_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107922","article-title":"Genotoxic therapy and resistance mechanism in gliomas","volume":"228","author":"Lang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104339_b0690","article-title":"High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma","volume":"14","author":"P\u00f6hlmann","year":"2024","journal-title":"Review Frontiers in Oncology"},{"key":"10.1016\/j.drudis.2025.104339_b0695","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1573394716666200721155514","article-title":"An overview of high-grade glioma: current and emerging treatment approaches","volume":"17","author":"Kavya","year":"2021","journal-title":"Curr Cancer Therapy Rev"},{"key":"10.1016\/j.drudis.2025.104339_b0700","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3390\/biomedicines10071531","article-title":"Ubiquitin-specific protease 6 n-terminal-like protein (USP6NL) and the epidermal growth factor receptor (EGFR) signaling axis regulates ubiquitin-mediated dna repair and temozolomide-resistance in glioblastoma","volume":"10","author":"Su","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2025.104339_b0705","first-page":"958","article-title":"Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity","volume":"17","author":"Qin","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2025.104339_b0710","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1021\/acs.molpharmaceut.2c00775","article-title":"Options of therapeutics and novel delivery systems of drugs for the treatment of melanoma","volume":"19","author":"Wang","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2025.104339_b0715","first-page":"326","article-title":"Chemotherapy resistance mechanisms in advanced skin cancer","volume":"11","author":"Kalal","year":"2017","journal-title":"Oncol Rev"},{"key":"10.1016\/j.drudis.2025.104339_b0720","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/jcp.31104","article-title":"OTUD4 regulates metastasis and chemoresistance in melanoma by stabilizing Snail1","volume":"238","author":"Gao","year":"2023","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2025.104339_b0725","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20171960","article-title":"Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies","volume":"215","author":"Saei","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104339_b0730","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/1535-7163.MCT-17-0919","article-title":"Targeting the proteasome-associated deubiquitinating enzyme USP14 impairs melanoma cell survival and overcomes resistance to MAPK-targeting therapies","volume":"17","author":"Didier","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104339_b0735","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/pcmr.13150","article-title":"MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14","volume":"37","author":"Li","year":"2024","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.drudis.2025.104339_b0740","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s10565-022-09729-x","article-title":"Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2","volume":"39","author":"Wu","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.drudis.2025.104339_b0745","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0750","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/febs.12737","article-title":"Long non-coding RNA UCA 1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling","volume":"281","author":"Fan","year":"2014","journal-title":"FEBS J"},{"key":"10.1016\/j.drudis.2025.104339_b0755","doi-asserted-by":"crossref","first-page":"12731","DOI":"10.1007\/s13277-016-5157-0","article-title":"CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory\/invasive potential in bladder cancer: the effect is autophagy-associated","volume":"37","author":"Yin","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.drudis.2025.104339_b0760","doi-asserted-by":"crossref","first-page":"11706","DOI":"10.3390\/ijms222111706","article-title":"PR-619, a general inhibitor of deubiquitylating enzymes, diminishes cisplatin resistance in urothelial carcinoma cells through the suppression of c-Myc: an in vitro and in vivo study","volume":"22","author":"Hsu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0765","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.4161\/cc.11.6.19550","article-title":"The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer","volume":"11","author":"Kim","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drudis.2025.104339_b0770","unstructured":"National Cancer Institute. Drugs Approved for Bone Cancer. www.cancer.gov\/about-cancer\/treatment\/drugs\/bone [Accessed March 13, 2025]."},{"key":"10.1016\/j.drudis.2025.104339_b0775","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1158\/1541-7786.MCR-23-0323","article-title":"USP1 expression driven by EWS::FLI1 transcription factor stabilizes survivin and mitigates replication stress in Ewing sarcoma","volume":"21","author":"Mallard","year":"2023","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0780","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/15548627.2022.2150003","article-title":"The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma","volume":"19","author":"Niu","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.drudis.2025.104339_b0785","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.pharmtox.46.120604.141300","article-title":"The proteasome and proteasome inhibitors in cancer therapy","volume":"46","author":"Voorhees","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drudis.2025.104339_b0790","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.drudis.2025.104339_b0795","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.1021\/jm300434z","article-title":"Molecular mechanisms of acquired proteasome inhibitor resistance","volume":"55","author":"Kale","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104339_b0800","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2025.104339_b0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2025.104339_b0810","doi-asserted-by":"crossref","first-page":"8949","DOI":"10.3390\/ijms25168949","article-title":"Different strategies to overcome resistance to proteasome inhibitors-a summary 20 years after their introduction","volume":"25","author":"Tyrna","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104339_b0815","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104339_b0820","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104339_b0825","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","article-title":"Deubiquitinase inhibition as a cancer therapeutic strategy","volume":"147","author":"D'Arcy","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104339_b0830","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1021\/acs.jmedchem.9b01138","article-title":"Advances in discovering deubiquitinating enzyme (DUB) inhibitors","volume":"26","author":"Schauer","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104339_b0835","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood.V124.21.3116.3116","article-title":"Targeted disruption of USP14 and UCHL5 with the novel deubiquitinase enzyme (DUB) inhibitor, VLX1570, induces immense proteotoxicity and cell death in malignant plasma cells","volume":"124","author":"Paulus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104339_b0840","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and\/or refractory multiple myeloma","volume":"38","author":"Rowinsky","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drudis.2025.104339_b0845","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/1440-1681.13049","article-title":"Inhibition of cancer stem cells promoted by pimozide","volume":"46","author":"Gon\u00e7alves","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.drudis.2025.104339_b0850","doi-asserted-by":"crossref","first-page":"13146","DOI":"10.1038\/s41598-018-31567-3","article-title":"Inhibiting multiple deubiquitinases to reduce androgen receptor expression in prostate cancer cells","volume":"8","author":"de Las","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104339_b0855","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/cbdd.12682","article-title":"Betulinic acid: recent advances in chemical modifications, effective delivery, and molecular mechanisms of a promising anticancer therapy","volume":"87","author":"Ali-Seyed","year":"2016","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2025.104339_b0860","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056234","article-title":"Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity","volume":"8","author":"Reiner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104339_b0865","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41389-018-0086-y","article-title":"Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer","volume":"7","author":"Xia","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.drudis.2025.104339_b0870","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.18632\/oncotarget.2904","article-title":"Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells","volume":"6","author":"Vogel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104339_b0875","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/imm.13683","article-title":"Deubiquitinase inhibitor PR-619 potentiates colon cancer immunotherapy by inducing ferroptosis","volume":"170","author":"Wu","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.drudis.2025.104339_b0880","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.7150\/thno.46109","article-title":"The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation","volume":"11","author":"Jing","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2025.104339_b0885","first-page":"218","article-title":"WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation","volume":"1","author":"Liu","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2025.104339_b0890","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-16-2692","article-title":"Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells","volume":"23","author":"Das","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104339_b0895","doi-asserted-by":"crossref","first-page":"12791","DOI":"10.18632\/oncotarget.7302","article-title":"Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo","volume":"7","author":"Karpel-Massler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104339_b0900","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/cancers12061579","article-title":"Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics","volume":"12","author":"Antao","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104339_b0905","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.drudis.2022.06.009","article-title":"Deubiquitinating enzymes: promising targets for drug resistance","volume":"27","author":"Ge","year":"2022","journal-title":"Drug Discov Today"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:38:31Z","timestamp":1762371511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":181,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1359644625000522"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104339","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging role of deubiquitinases in modulating cancer chemoresistance","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104339"}}